Thu, May 15, 6:34 PM (8 days ago)
**America Great Health (AGH) - Q1 2025 Financial Summary** **Company Overview:** America Great Health (AGH, Ticker: AAGH) is a Wyoming-based healthcare company focused on protein and peptide drug research, diagnostic devices, cell therapy, and supplements. AGH operates several subsidiaries in the U.S. and China. **Financial Health:** * **Revenue:** Q1 2025 revenue was $56,148,000, up from $94,032,000 in Q1 2024, driven by new product launches. * **Profit Margins:** Gross profit margin was 89% in Q1 2025, while the net loss margin was -282%. * **Cash Flow:** Net cash used in operating activities was $60,297,000 in Q1 2025, a decrease of $389,903,000 from Q1 2024. Net cash provided by financing activities was $43,314,000. * **Earnings Changes:** Net loss for Q1 2025 was $158,377,000, a decrease of $70,130,000 from Q1 2024. * **Liquidity:** AGH had $36,880,000 in cash as of March 31, 2025, with a shareholders' deficit of $5,709,609,000. **Performance Metrics:** * **Sales Growth:** Sales increased by 59% YoY due to new product launches. * **Operating Expenses:** Operating expenses decreased by 1% YoY. * **Net Loss Improvement:** Net loss decreased by 28% YoY. **Trends and Uncertainties:** * AGH is focusing on innovative technologies and business development in the healthcare ecosystem. * The company is facing substantial doubt about its ability to continue as a going concern within the next twelve months. * AGH is raising additional capital to achieve profitable operations and meet ongoing general and administrative expenses. **Future Operations Impact:** * AGH plans to continue investing in protein and peptide drug research, diagnostic devices, and cell therapy. * The company aims to achieve profitable operations and secure additional sources of capital. * AGH's new majority shareholders will provide all working capital going forward. **Disclosure Controls and Procedures:** * AGH's management concluded that its disclosure controls and procedures are not effective. * Material weaknesses include a lack of a functioning audit committee, accounting staff, independent directors, and an effective review process. **Subsequent Events:** * On April 8, 2025, AGH signed a loan agreement for $100,000 with an annual interest rate of 20%. * On April 14, 2025, AGH issued 1,900,000 shares to an unrelated party for introducing investors to purchase the company's stocks.